Thermo Fisher Scientific announced a new suite of Ion Torrent Oncomine immune repertoire assays designed to detect potentially malignant clones of T-cells and B-cells, which play a key role in the immune response system. Using proprietary Ion AmpliSeq technology, the new pan-clonality assays target multiple parts of the B- and T-cell immune receptors using a single reaction with ultra-high sensitivity, thereby increasing the probability of malignant clone detection and decreasing the time to results. Detection of distinct receptor DNA sequences can inform diagnostic, prognostic and therapy development studies in the progression of lymphoid cancers including leukemias, lymphomas and diseases such as multiple myeloma. Using next-generation sequencing (NGS) technology, detection sensitivity can be increased compared to traditional testing methods such as flow cytometry or qPCR. One of the challenges of current NGS-based immune repertoire analysis has been the need to run multiple secondary tests due to the high test-failure rates of a typical single NGS assay. The new Oncomine pan-clonality assays overcome this challenge by uniquely targeting multiple parts of the receptor to reduce the need for secondary tests and increase the probability that a single assay can detect a potentially malignant clone. Thermo Fisher's new suite of immune repertoire assays are available on the Ion GeneStudio S5 System and feature integrated analysis and data visualization tools that simplify the interpretation of results for laboratories and healthcare professionals.